Thursday, February 18, 2021

Ensysce Biosciences Sets CFO

San Diego-based Ensysce Biosciences, a biopharmaceuticals company developing medicines for severe pain relief to reduce fear of addiction, opioid misuse, abuse and overdose, says it has appointed David Humphrey as its new Chief Financial Officer. The company--which is in the midst of being acquired by Leisure Acquisition Corp., a special purpose acquisition company (SPAC)--said Humphrey was previously CFO of Senomyx, where he had been when it was acquired by Firmenich SA. Ensysce said that Humphrey will oversee financial strategy and business expansion at Ensysce, in addition to assisting with Ensysce's proposed business combination with LACQ.

---